Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2007 Jul 11;13(2):260–277. doi: 10.1111/j.1527-3458.2007.00014.x

DP‐155, a Lecithin Derivative of Indomethacin, is a Novel Nonsteroidal Antiinflammatory Drug for Analgesia and Alzheimer's Disease Therapy

Eran Dvir 1,✉, Anat Elman 2, Danielle Simmons 3, Israel Shapiro 1, Revital Duvdevani 1, Arik Dahan 4, Amnon Hoffman 4, Jonathan E Friedman 1
PMCID: PMC6726352  PMID: 17627676

ABSTRACT

DP‐155 is a lipid prodrug of indomethacin that comprises the latter conjugated to lecithin at position sn‐2 via a 5‐carbon length linker. It is cleaved by phospholipase A2 (PLA)2 to a greater extent than similar compounds with linkers of 2, 3, and 4 carbons. Indomethacin is the principal metabolite of DP‐155 in rat serum and, after DP‐155 oral administration, the half‐life of the metabolite was 22 and 93 h in serum and brain, respectively, compared to 10 and 24 h following indomethacin administration. The brain to serum ratio was 3.5 times higher for DP‐155 than for indomethacin. In vitro studies demonstrated that DP‐155 is a selective cyclooxygenase (COX)‐2 inhibitor. After it is cleaved, its indomethacin derivative nonselectively inhibits both COX‐1 and ‐2. DP‐155 showed a better toxicity profile probably due to the sustained, low serum levels and reduced maximal concentration of its indomethacin metabolite. DP‐155 did not produce gastric toxicity at the highest acute dose tested (0.28 mmol/kg), while indomethacin caused gastric ulcers at a dose 33‐fold lower. Furthermore, after repeated oral dosing, gastrointestinal and renal toxicity was lower (10‐ and 5‐fold, respectively) and delayed with DP‐155 compared to indomethacin. In addition to reduced toxicity, DP‐155 had similar ameliorative effects to indomethacin in antipyretic and analgesia models. Moreover, DP‐155 and indomethacin were equally efficacious in reducing levels of amyloid ß (Aß)42 in transgenic Alzheimer's disease mouse (Tg2576) brains as well as reducing Aß42 intracellular uptake, neurodegeneration, and inflammation in an in vitro AD model. The relatively high brain levels of indomethacin after DP‐155 administration explain the equal efficacy of DP‐155 despite its low systemic blood concentrations. Compared to indomethacin, the favored safety profile and equal efficacy of DP‐155 establish the compound as a potential candidate for chronic use to treat AD‐related pathology and for analgesia.

Keywords: Gastrointestinal, Phospholipid, Prodrug, Renal, Toxicity

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Conflict of Interest. E. Dvir and A. Hahan were employed by D‐Pharm‐Ltd, The manufacturer of D‐155, during the development of the drug. I. Shapiro, R. Duvdevani, and J. Friedman are currently employed by D‐Pharm, Ltd.

REFERENCES

  1. Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, Small GW, Cole GM, Barrio JR (2003) In vitro detection of (S)‐naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2‐(1‐[6‐[(2‐[(18)F]fluoroethyl)(methyl)amino]‐2‐naphthyl]ethylidene)malono nitrile. Neuroscience 117:723‐730. [DOI] [PubMed] [Google Scholar]
  2. Arnold L, Collins C, Starmer GA (1974) Renal and gastric lesions after phenylbutazone and indomethacin in the rat. Pathology 6:303‐313. [DOI] [PubMed] [Google Scholar]
  3. Ayano Y, Yamasaki K, Soejima H, Ikegami K (1984) Role of the renal prostaglandins in furosemide‐induced diuresis. Urol Int 39:25‐28. [DOI] [PubMed] [Google Scholar]
  4. Bi X, Gall CM, Zhou J, Lynch G (2002) Uptake and pathogenic effects of amyloid beta peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112:827‐840. [DOI] [PubMed] [Google Scholar]
  5. Chapman PF, White GL, Jones MW, Cooper‐Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, et al (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271‐276. [DOI] [PubMed] [Google Scholar]
  6. Citron M, Vigo‐Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ (1994) Excessive production of amyloid beta‐protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 91:11993‐11997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clark WG, Cumby HR (1975) The antipyretic effect of indomethacin. J Physiol 248:625‐638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ (2002) Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling. J Neurosci Res 70:462‐473. [DOI] [PubMed] [Google Scholar]
  9. D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38:120‐134. [DOI] [PubMed] [Google Scholar]
  10. Dahan A, Duvdevani R, Dvir E, Elmann A, Hoffman A (2007) A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In‐vivo and in‐vitro evaluation of an indomethacin‐lecithin conjugate. J Control Release 119:86‐93. [DOI] [PubMed] [Google Scholar]
  11. De Souza GE, Cardoso RA, Melo MC, Fabricio AS, Silva VM, Lora M, De Brum‐Fernandes AJ, Rae GA, Ferreira SH, Zampronio AR (2002) A comparative study of the antipyretic effects of indomethacin and dipyrone in rats. Inflamm Res 51:24‐32. [DOI] [PubMed] [Google Scholar]
  12. DeLeo JA, Colburn RW, Coombs DW, Ellis MA (1989) The differentiation of NSAIDs and prostaglandin action using a mechanical visceral pain model in the rat. Pharmacol Biochem Behav 33:253‐255. [DOI] [PubMed] [Google Scholar]
  13. Dormond O, Foletti A, Paroz C, Ruegg C (2001) NSAIDs inhibit alpha V beta 3 integrin‐mediated and Cdc42/Rac‐dependent endothelial‐cell spreading, migration and angiogenesis. Nat Med 7:1041‐1047. [DOI] [PubMed] [Google Scholar]
  14. Dvir E, Friedman JE, Lee JY, Koh JY, Younis F, Raz S, Shapiro I, Hoffman A, Dahan A, Rosenberg G, et al (2006) A novel phospholipid derivative of indomethacin, DP‐155 [mixture of 1‐steroyl and 1‐palmitoyl‐2‐{6‐[1‐(p‐chlorobenzoyl)‐5‐methoxy‐2‐methyl‐3‐indolyl acetamido]hexanoyl}‐sn‐glycero‐3‐phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J Pharmacol Exp Ther 318:1248‐1256. [DOI] [PubMed] [Google Scholar]
  15. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH et al (2003) NSAIDs and enantiomers of flurbiprofen target gamma‐secretase and lower Abeta 42 in vivo . J Clin Invest 112:440‐449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fries JF, Singh G, Ramey DR (1998) The clinical epidemiology of non‐steroidal anti‐inflammatory drug gastropathy, in Clinical Significance and Potential of Selective COX‐2 Inhibitors (Vane J. and Botting R. eds) pp 57‐65, William Harvey Press, London . [Google Scholar]
  17. Garcia‐Vicuna R, Diaz‐Gonzalez F, Gonzalez‐Alvaro I, Del Pozo MA, Mollinedo F, Cabanas C, Gonzalez‐Amaro R, Sanchez‐Madrid F (1997) Prevention of cytokine‐induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. Arthritis Rheum 40:143‐153. [DOI] [PubMed] [Google Scholar]
  18. Gasparini L, Ongini E, Wenk G (2004) Non‐steroidal anti‐inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action. J Neurochem 91:521‐536. [DOI] [PubMed] [Google Scholar]
  19. Giraud MN, Motta C, Romero JJ, Bommelaer G, Lichtenberger LM (1999) Interaction of indomethacin and naproxen with gastric surface‐active phospholipids: A possible mechanism for the gastric toxicity of nonsteroidal anti‐inflammatory drugs (NSAIDs). Biochem Pharmacol 57:247‐254. [DOI] [PubMed] [Google Scholar]
  20. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, et al (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156:15‐20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Halliday G, Robinson SR, Shepherd C, Kril J (2000a) Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 27:1‐8. [DOI] [PubMed] [Google Scholar]
  22. Halliday GM, Shepherd CE, McCann H, Reid WG, Grayson DA, Broe GA, Kril JJ (2000b) Effect of anti‐inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 57:831‐836. [DOI] [PubMed] [Google Scholar]
  23. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, et al (1998) Accelerated Alzheimer‐type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97‐100. [DOI] [PubMed] [Google Scholar]
  24. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99‐102. [DOI] [PubMed] [Google Scholar]
  25. Hu XH, Tang HW, Li QS, Huang XF (1994) Central mechanism of indomethacin analgesia. Eur J Pharmacol 263:53‐57. [DOI] [PubMed] [Google Scholar]
  26. Ivanov IT, Tzaneva M (2002) Direct cytotoxicity of non‐steroidal anti‐inflammatory drugs in acidic media: Model study on human erythrocytes with DIDS‐inhibited anion exchanger. Pharmazie 57:848‐851. [PubMed] [Google Scholar]
  27. Jurna I, Brune K (1990) Central effect of the non‐steroid anti‐inflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in C fibre‐evoked activity in single neurones of the rat thalamus. Pain 41:71‐80. [DOI] [PubMed] [Google Scholar]
  28. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age‐dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372‐381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kudo I, Murakami M (2002) Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68–69:3‐58. [DOI] [PubMed] [Google Scholar]
  30. Kurz M, Scriba GK (2000) Drug‐phospholipid conjugates as potential prodrugs: Synthesis, characterization, and degradation by pancreatic phospholipase A(2). Chem Phys Lipids 107:143‐157. [DOI] [PubMed] [Google Scholar]
  31. Lambert DM (2000) Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 11 (Suppl 2):S15‐27. [DOI] [PubMed] [Google Scholar]
  32. Leyck S, Dereu N, Etschenberg E, Ghyczy M, Graf E, Winkelmann J, Parnham MJ (1985) Improvement of the gastric tolerance of non‐steroidal anti‐inflammatory drugs by polyene phosphatidylcholine (Phospholipon 100). Eur J Pharmacol 117:35‐42. [DOI] [PubMed] [Google Scholar]
  33. Lin B, Arai AC, Lynch G, Gall CM (2003) Integrins regulate NMDA receptor‐mediated synaptic currents. J Neurophysiol 89:2874‐2878. [DOI] [PubMed] [Google Scholar]
  34. MacDonald TM (2000) Epidemiology and pharmacoeconomic implications of non‐steroidal anti‐inflammatory drug‐associated gastrointestinal toxicity. Rheumatology (Oxford) 39 (Suppl 2):13‐20; discussion 57‐19. [DOI] [PubMed] [Google Scholar]
  35. Markus HS, Vallance P, Brown MM (1994) Differential effect of three cyclooxygenase inhibitors on human cerebral blood flow velocity and carbon dioxide reactivity. Stroke 25:1760‐1764. [DOI] [PubMed] [Google Scholar]
  36. McCulloch J, Kelly PA, Grome JJ, Pickard JD (1982) Local cerebral circulatory and metabolic effects of indomethacin. Am J Physiol 243:H416‐H423. [DOI] [PubMed] [Google Scholar]
  37. McGeer PL, McGeer EG (1999) Inflammation of the brain in Alzheimer's disease: Implications for therapy. J Leukoc Biol 65:409‐415. [DOI] [PubMed] [Google Scholar]
  38. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28:639‐647. [DOI] [PubMed] [Google Scholar]
  39. McMahon SB (1997) Are there fundamental differences in the peripheral mechanisms of visceral and somatic pain? Behav Brain Sci 20:381‐391; discussion 435–513. [DOI] [PubMed] [Google Scholar]
  40. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler et al (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274:6483‐6492. [DOI] [PubMed] [Google Scholar]
  41. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21:4183‐4187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Psaty BM, Furberg CD (2005) COX‐2 inhibitors—lessons in drug safety. N Engl J Med 352:1133‐1135. [DOI] [PubMed] [Google Scholar]
  43. Roberts LJI, Morrow JD (2001) Analgesic‐antipyretic and anitiinflammatory agents and drugs employed in the treatment of gout, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE. and Gilman AG. eds) pp 687‐731, McGraw‐Hill, New York . [Google Scholar]
  44. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P et al. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609‐1611. [DOI] [PubMed] [Google Scholar]
  45. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P (1996) Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17:681‐686. [DOI] [PubMed] [Google Scholar]
  46. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al (1996) Secreted amyloid beta‐protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864‐870. [DOI] [PubMed] [Google Scholar]
  47. Schwab JM, Schluesener HJ, Meyermann R, Serhan CN (2003) COX‐3 the enzyme and the concept: Steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot Essent Fatty Acids 69:339‐343. [DOI] [PubMed] [Google Scholar]
  48. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA (1996) Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis 3:51‐63. [DOI] [PubMed] [Google Scholar]
  49. Stichtenoth DO, Frölich JC (1998) Avoidance of renal side effects of non‐steroidal anti‐inflammatory drugs: Value of selective cyclooxygenase‐2 inhibition, in Clinical Significance and Potential of Selective COX‐2 Inhibitors (Vane J. and Botting R. eds) pp 99‐108, William Harvey Press, London . [Google Scholar]
  50. Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM, Pratico D (2004) Modulation of nuclear factor‐kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165:2197‐2206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Tabet N, Feldman H (2002) Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev:CD003673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161:1869‐1879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Thomas T, Nadackal TG, Thomas K (2001) Aspirin and non‐steroidal anti‐inflammatory drugs inhibit amyloid‐beta aggregation. Neuroreport 12:3263‐3267. [DOI] [PubMed] [Google Scholar]
  54. T' Veld BA, Ruitenberg A, Hofman A, Launer LJ, Van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515‐1521. [DOI] [PubMed] [Google Scholar]
  55. Vogel HG, Vogel WH (1997) Drug Discovery and Evaluation Pharmcological Assays. Springer, Berlin . [Google Scholar]
  56. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212‐216. [DOI] [PubMed] [Google Scholar]
  57. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH (2003) Evidence that nonsteroidal anti‐inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma‐secretase activity. J Biol Chem 278:31831‐31837. [DOI] [PubMed] [Google Scholar]
  58. Weyant MJ, Carothers AM, Bertagnolli ME, Bertagnolli MM (2000) Colon cancer chemopreventive drugs modulate integrin‐mediated signaling pathways. Clin Cancer Res 6:949‐956. [PubMed] [Google Scholar]
  59. Whittle BJR (1998) Experimental basis for non‐steroidal anti‐inflammatory drug‐induced gut injury, in Clinical Significance and Potential of Selective COX‐2 Inhibitors (Vane J. and Botting R. eds) pp 67‐76, William Harvey Press, London . [Google Scholar]
  60. Willoughby DA, Moore AR, Colville‐Nash PR (2000) COX‐1, COX‐2, and COX‐3 and the future treatment of chronic inflammatory disease. Lancet 355:646‐648. [DOI] [PubMed] [Google Scholar]
  61. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA (2001) Intraneuronal Abeta accumulation precedes plaque formation in beta‐amyloid precursor protein and presenilin‐1 double‐transgenic mice. Neurosci Lett 306:116‐120. [DOI] [PubMed] [Google Scholar]
  62. Yazawa K, Tsuno NH, Kitayama J, Kawai K, Okaji Y, Asakage M, Sunami E, Kaisaki S, Hori N, Watanabe T, et al (2005) Selective inhibition of cyclooxygenase‐2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin. Cancer Sci 96:93‐99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Zipp F, Aktas O (2006) The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29:518‐527. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES